Scholar Rock’s Shares Soar 300% After Phase III Win in ... - BioSpace

Oct 8, 2024 · Scholar Rock on Monday announced that its investigational myostatin blocker apitegromab aced the Phase III SAPPHIRE trial in spinal muscular atrophy, demonstrating …

CouponFollow Extension

300%
OFF

Scholar Rock’s Shares Soar 300% After Phase III Win In ... - BioSpace

3 weeks from now

Oct 8, 2024 · Scholar Rock on Monday announced that its investigational myostatin blocker apitegromab aced the Phase III SAPPHIRE trial in spinal muscular atrophy, demonstrating …

biospace.com

300%
OFF

Scholar Rock’s Stock Skyrockets 300% Following Successful Phase …

3 weeks from now

Oct 8, 2024 · Successful Phase III Trial: Scholar Rock's apitegromab, a monoclonal antibody targeting myostatin, demonstrated statistically significant and clinically meaningful …

talk.bio

300%
OFF

Scholar Rock Shares Jump 300% After Rare Disease Drug Scores Trial …

3 weeks from now

Oct 7, 2024 · Scholar Rock's experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its shares soaring …

reuters.com

$300
OFF

Scholar Rock Scores $300M For Regulatory Filings & Launch Plans …

3 weeks from now

Oct 9, 2024 · On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock …

medcitynews.com

300%
OFF

Scholar Rock’s Shares Soar 300% After Phase III Win In Spinal …

3 weeks from now

Aug 10, 2024 · With Monday’s data from SAPPHIRE, Scholar Rock is building toward regulatory submissions for apitegromab in spinal muscular atrophy in the first quarter of 2025.

convitgroup.com

320%
OFF

Scholar Rock (SRRK) Shares Soar Over 320% On SMA Topline …

3 weeks from now

New York, October 07, 2024 - PRISM MarketView - The late-stage biopharmaceutical company Scholar Rock (SRRK) who focuses on treatments for spinal muscular atrophy (SMA), …

prismmarketview.com

319%
OFF

Scholar Rock Soars On Spinal Muscular Atrophy Phase III Data

3 weeks from now

Oct 7, 2024 · Shares of Scholar Rock Holding Corp. (NASDAQ:SRRK) soared $23.69, or 319%, to $31.11 after the Cambridge, Mass.-based firm disclosed positive top-line data from the …

bioworld.com

300%
OFF

BioSpace On LinkedIn: Scholar Rock’s Shares Soar 300% After …

3 weeks from now

BioSpace 118,606 followers 2h With Monday’s data from SAPPHIRE, Scholar Rock is building toward regulatory submissions for apitegromab in spinal muscular atrophy in the first quarter of …

linkedin.com

335%
OFF

Scholar Rock Holding (SRRK) Stock Rockets Up On Positive Phase …

3 weeks from now

Oct 9, 2024 · Scholar Rock Holding (SRRK) has shown a staggering 335% jump in share price following the success of its spinal muscular atrophy (SMA) treatment drug, Apitegromab, in a …

nasdaq.com

300%
OFF

David Hallal On LinkedIn: Scholar Rock Reports Apitegromab …

3 weeks from now

Scholar Rock’s Shares Soar 300% After Phase III Win in Spinal Muscular Atrophy

linkedin.com

$300
OFF

Scholar Rock Announces Pricing Of Upsized $300 Million

3 weeks from now

Oct 9, 2024 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative …

biospace.com

300%
OFF

Scholar Rock Shares Jump 300% After Rare Disease Drug Scores Trial …

3 weeks from now

Oct 7, 2024 · Scholar Rock's NASDAQ:SRRK experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its …

tradingview.com

300%
OFF

BioSpace - With Monday’s Data From SAPPHIRE, Scholar Rock.

3 weeks from now

#muscularatrophy #pharma #biospace biospace.com Scholar Rock’s Shares Soar 300% After Phase III Win in Spinal Muscular Atrophy

facebook.com

FAQs about Scholar Rock’s Shares Soar 300% After Phase III Win in ... - BioSpace Coupon?

How much did Scholar Rock Raise in a stock offering?

On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock offering. U.S. and European regulatory submissions for the drug are now planned for early 2025. ...

Why did Scholar Rock's stock increase 362% After Phase III data?

Scholar Rock’s stock price increased by 362% after the company announced its Phase III data. Scholar Rock is looking to file for regulatory approval in the US and EU after the positive data. Image credit: Shutterstock / eamesBot ...

Will scholar rock get regulatory approval after positive SMA results?

Scholar Rock is looking to file for regulatory approval in the US and EU after the positive data. Image credit: Shutterstock / eamesBot Scholar Rock’s stock has soared off the back of positive Phase III results from its spinal muscular atrophy (SMA) candidate. ...

Should you buy scholar rock holding (SRRK) stock?

Scholar Rock Holding is rated a Strong Buy based on the cumulative recommendations of five analysts. The average price target for SRRK stock is $29.67, representing a potential 0.61% change from current levels. Scholar Rock has recently announced success in a phase 3 trial, sparking a remarkable surge in the company’s share price. ...

Can scholar rock raise $42 million?

Scholar Rock has also granted underwriters a 30-day option to purchase up to 1.5 million shares of stock at the public offering price, which could raise $42 million more. ...

Will scholar rock be able to commercialize apitegromab?

Based on these promising results, Scholar Rock will submit applications to the FDA and the EMA in the first quarter of 2025. Furthermore, the company initiated an underwritten public offering of $275 million of shares of its common stock to support commercialization efforts for Apitegromab, among other operational needs. ...